1.220 makale bulundu

Kinh Vietnamca'da Parkinson hastalığı olan LRRK2 R1628P varyantının birleşmesi: Kesitsel bir çalışma.

Association of LRRK2 R1628P variant with Parkinson's disease in Kinh Vietnamese: a cross-sectional study.

Do MD, Tran TN, Le LHG, Mai TP.

Neurogenetics · 2025-07-31

DOI: 10.1007/s10048-025-00840-9PMID: 40742407

Novel Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors for the Treatment of Parkinson's Disease.

Song Z, Liang SH.

ACS Med Chem Lett · 2025-07-30

DOI: 10.1021/acsmedchemlett.5c00438PMID: 40832511

Parkinson Hastalığında LRRK2 p.V1447L'nin Fonksiyonel ve Yapısal Karakterizasyonu.

Functional and Structural Characterization of LRRK2 p.V1447L in Parkinson's Disease.

Pratuseviciute N, Lis P, Weber S, Gruchy N, Arnaud L, Alessi DR, Sammler E.

Mov Disord · 2025-07-30

DOI: 10.1002/mds.30284PMID: 40879463

Stable two-year longitudinal clinical outcomes in LRRK2 G2019S non-manifest carriers in a remote nationwide study.

Barbosa W, Auinger P, Pawlik M, Hartman E, Sharma S, Valdovinos BY, Wilson R, Norcliffe-Kaufmann L, Rowbotham H, Alcalay RN, Biglan K, Kinel D, Tanner CM, Holloway RG, Dorsey ER, Schneider RB.

Parkinsonism Relat Disord · 2025-07-21

DOI: 10.1016/j.parkreldis.2025.107969PMID: 40701123

PPM1M, Parkinson hastalığına potansiyel bir bağlantıya sahip bir LRRK2-counteracting, fosphoRab12-prefering fosfataz.

PPM1M, an LRRK2-counteracting, phosphoRab12-preferring phosphatase with a potential link to Parkinson's disease.

Chiang CY, Pratuseviciute N, Lin YE, Adhikari A, Yeshaw WM, Flitton C, Sherpa PL, Tonelli F, Rektorova I, Lynch T, Siuda J, Rudzińska-Bar M, Pulyk O, Bauer P, Beetz C, Dickson DW, Ross OA, Wszolek ZK, Global Parkinson’s Genetics Program (GP2), Fang ZH, Klein C, Zimprich A, Alessi DR, Sammler EM, Pfeffer SR.

Cell Rep · 2025-07-20

DOI: 10.1016/j.celrep.2025.116031PMID: 40690364

Parkinson hastalığı tedavisi için LRRK2'yi hedeflemede son gelişmeler.

Recent advances in targeting LRRK2 for Parkinson's disease treatment.

Karami M, Sanaye PM, Ghorbani A, Amirian R, Goleij P, Babamohamadi M, Izadi Z.

J Transl Med · 2025-07-08

DOI: 10.1186/s12967-025-06354-0PMID: 40629324

Parkinson hastalığı <i>LRRK2</i>-R1441C mutasyonu ile ilişkilidir: Karakterizasyon ve diğer <i>LRRK2</i> mutasyonları ile karşılaştırma.

Parkinson's disease associated with <i>LRRK2</i>-R1441C mutation: Characterization and comparison with other <i>LRRK2</i> mutations.

Hadad R, Alcalay RN, Senderova I, Nassar M, Milicic A, Peretz JA, Allen IE, Ben-Hayun R, Chasnyk N, Morani I, Elkoshi N, Valcour V, Schlesinger I.

J Parkinsons Dis · 2025-07-04

DOI: 10.1177/1877718x251354986PMID: 40611668

Mutant LRRK2'nin mutant GBA1-bağlantılı Parkinson hastalığı üzerindeki modifiye etkisi.

The modifying effect of mutant LRRK2 on mutant GBA1-associated Parkinson disease.

Serebryany-Piavsky V, Egulsky L, Manoim-Wolkovitz JE, Anis S, Hassin-Baer S, Parnas M, Horowitz M.

Hum Mol Genet · 2025-07-01

DOI: 10.1093/hmg/ddaf062PMID: 40315377

⁇ - LRRK2 Parkinson hastalığında sinüklein patolojisi.

α-Synuclein pathology in LRRK2 Parkinson disease.

Fyfe I.

Nat Rev Neurol · 2025-07-01

DOI: 10.1038/s41582-025-01113-7PMID: 40533524

Correction to: The modifying effect of mutant LRRK2 on mutant GBA1-associated Parkinson disease.

Yazar bilgisi kaynakta kontrol edilmeli

Hum Mol Genet · 2025-07-01

DOI: 10.1093/hmg/ddaf112PMID: 40554637

Parkinson hastalığı bağlantılı <i>LRRK2</i>-mutant farelerin kinaz inhibitörü tedavisi ile striatal nöroprotektif yolların restorasyonu.

Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinson's disease-linked <i>LRRK2</i>-mutant mice.

Jaimon E, Lin YE, Tonelli F, Antico O, Alessi DR, Pfeffer SR.

Sci Signal · 2025-07-01

DOI: 10.1126/scisignal.ads5761PMID: 40591712

Hafif Kronik Kolit, Parkinson Hastalığı ile Farelerde İntracerebral Enflamasyonu LRRK2-Medyalı NF- ⁇ B Aktivasyonu ve Nrf2'nin İnhibisyonu Yönetmeliği ile Arttırır.

Mild Chronic Colitis Exacerbates Intracerebral Inflammation in Mice with Parkinson's Disease Through LRRK2-Mediated Regulation of NF-κB Activation and Inhibition of Nrf2.

Yang M, Ke L, Geng Y, Hu P, Qiu Y, Liu Z, Zhang X, Wan F, Jacob JA, Liao J.

J Inflamm Res · 2025-06-27

DOI: 10.2147/jir.s526777PMID: 40606593